The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer.
 
Mary Frances Wedekind
No Relationships to Disclose
 
Jaydira Del Rivero
No Relationships to Disclose
 
Fernanda Irene Arnaldez
Employment - Novartis
Leadership - MacroGenics
Stock and Other Ownership Interests - IntelSat; Kite, a Gilead company; Macrogenics
 
Ramaprasad Srinivasan
Research Funding - AstraZeneca (Inst); Calithera Biosciences (Inst); Peloton Therapeutics (Inst); Sanofi (Inst)
 
Melissa Spencer
No Relationships to Disclose
 
Seth M. Steinberg
No Relationships to Disclose
 
Cody J. Peer
No Relationships to Disclose
 
William Douglas Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); TRACON Pharma (Inst)
 
Jonathan Keith Killian
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Paul S. Meltzer
Research Funding - Genzyme (Inst)
 
W. Marston Linehan
No Relationships to Disclose
 
Brigitte C. Widemann
No Relationships to Disclose
 
John Glod
Research Funding - AdaptImmune; GlaxoSmithKline/Adaptimmune (Inst)